For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020

PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020

ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.

More >>
 
An interview with Senior Investigator Annette Hay

An interview with Senior Investigator Annette Hay

Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.

More >>
 
Complementary Medications and outcomes in CCTG trials.

Palliative and supportive care presentation at ESMO 2019

Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by CCTG also used complementary medicines.

More >>
 

Cell Therapy’s Promise for Canadians Must Include Access

An emerging form of immunotherapy, called adoptive cell transfer, has the potential to transform the way in which cancers are treated.

More >>
 

Planned trials

HD11

Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

HDC1

Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

More >>

MA40

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)

More >>

OV26

Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy

More >>

PAC3

Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer

PR22

Darolutamide Augments Standard Therapy for Localized High-Risk Prostate Cancer (DASL-HiCaP)

More >>

Recently activated

BL13F

A Prospective Feasibility Sub-Study of BL13 - [e-PRISM]

More >>

BRC8

MRI Surveillance with or without Prophylactic Cranial Irradiation in SCLC

More >>

CEC7

Post-Surgical (SRS) Compared with (FSRS) for Resected Metastatic Brain Disease

More >>

CX6

International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer SENTICOL III

More >>

GCC1

Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumours

More >>

I234G

Carboplatin in Metastatic Castration-Resistant Prostate Cancer

More >>

IC8

COV-IMMUNO - Immunization with IMM-101 vs Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

More >>

ICC1

NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study

More >>

ME15

1cm vs 2cm Wide Excision Margins for Primary Cutaneous Melanoma (MelMarT-II)

More >>

PM1S

Genomic Analysis in Cancer Patients: A Pan-Canadian Survey of Oncologists and Patients

More >>

SC27

Impact of COVID-19 Pandemic on Cancer Patients During Treatment and Survivors

More >>
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 
TAILORx / MAC.12 breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer.

TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancer

Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
 
Award recipients

Canadian Cancer Research Alliance announces award winners

Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.

More >>
 

Publications

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience

Breast Cancer Res Treat , 2020
Dent SF;Botros J;Rushton M;Aseyev O;Levine MN;Parulekar WR;OGCOBrien P;Burnell M;Pritchard KI;Chen BE;Shepherd LE;

More >>

Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial (ONLINE)

Cancer n/a, 2020
Moku P;Shepherd L;Ali SM;Leitzel K;Parulekar WR;Zhu L;Virk S;Nomikos D;Aparicio S;Gelmon K;Drabick J;Cream L;Halstead ES;Umstead TM;Mckeone D;Polimera H;Maddukuri A;Ali A;Nagabhairu V;Poulose J;Pancholy N;Spiegel H;Chen BE;Lipton A;

More >>

The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance)

Cancer Epidemiol Biomarkers Prev 29: 1692, 2020
Cheng E;Zhang S;Ou FS;Mullen B;Ng K;Saltz LB;Niedzwiecki D;Mayer RJ;Mowat RB;Whittom R;Hantel A;Benson A;Atienza D;Messino M;Kindler H;Giovannucci EL;Van Blarigan EL;Meyerhardt JA;Fuchs CS;

More >>

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial (ONLINE)

The Lancet , 2020
Parker CC;Clarke NW;Cook AD;Kynaston HG;Petersen PM;Catton C;Cross W;Logue J;Parulekar W;Payne H;Persad R;Pickering H;Saad F;Anderson J;Bahl A;Bottomley D;Brasso K;Chahal R;Cooke PW;Eddy B;Gibbs S;Goh C;Gujral S;Heath C;Henderson A;Jaganathan R;Jakobsen H;James ND;Kanaga Sundaram S;Lees K;Lester J;Lindberg H;Money-Kyrle J;Morris S;O'Sullivan J;Ostler P;Owen L;Patel P;Pope A;Popert R;Raman R;Roder MA;Sayers I;Simms M;Wilson J;Zarkar A;Parmar MKB;Sydes MR;

More >>

Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial (ONLINE)

JAMA Oncology , 2020
Sridhar SS;Blais N;Tran B;Reaume MN;North SA;Stockler MR;Chi KN;Fleshner NE;Liu G;Robinson JW;Mukherjee SD;Rahim Y;Winquist E;Booth CM;Nguyen NT;Beardsley EK;Alimohamed NS;McDonald GT;Ding K;Parulekar WR;

More >>

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience

Breast Cancer Res Treat , 2020
Dent SF;Botros J;Rushton M;Aseyev O;Levine MN;Parulekar WR;O'Brien P;Burnell M;Pritchard KI;Chen BE;Shepherd LE;

More >>

Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial (ONLINE)

Breast Cancer Res Treat , 2020
Ho V;Pasquet R;Luo S;Chen G;Goss P;Tu D;Lazarus P;Richardson H;

More >>

Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients

Journal of Neuro-Oncology 149: 65 - 71, 2020
Climans SA;Brandes AA;Cairncross JG;Ding K;Fay M;Laperriere N;Menten J;Nishikawa R;O'Callaghan CJ;Perry JR;Phillips C;Roa W;Wick W;Winch C;Mason WP;

More >>